Cargando…
Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma
BACKGROUND: Osteosarcoma (OS) is a rare bone tumor with a high propensity for lung metastasis and poor patient outcomes. It is crucial to identify novel therapeutic strategies and biomarkers. PATIENTS AND METHODS: ARK1C1 staining was detected in OS specimens, and its clinical significance was assess...
Autores principales: | Wang, Liang, Liu, Yang, Yu, Guanzhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353227/ https://www.ncbi.nlm.nih.gov/pubmed/30774369 http://dx.doi.org/10.2147/OTT.S165647 |
Ejemplares similares
-
Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling
por: Gao, Yunshu, et al.
Publicado: (2021) -
FoxM1 is Upregulated in Osteosarcoma and Inhibition of FoxM1 Decreases Osteosarcoma Cell Proliferation, Migration, and Invasion
por: Zhu, Xia, et al.
Publicado: (2020) -
FoxM1 Is a General Target for Proteasome Inhibitors
por: Bhat, Uppoor G., et al.
Publicado: (2009) -
Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases
por: Hasan, Md Kamrul, et al.
Publicado: (2022) -
ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1
por: Jiao, Xiaodong, et al.
Publicado: (2018)